Tier 2 — strong

Efficacy, Safety, and Cost-Effectiveness of N-Acetylcysteine in Preventing Amphotericin B Nephrotoxicity in Egyptian Patients with Hematological Malignancies: A Randomized Controlled Trial

Abdel-Hameed Ibrahim Mohamed Ebid, Haydi Sayed Mohamed, Yasmin Medhat Monir Mohammed, Sara Mohamed Mohamed Abdel Motaleb
Hosp Pharm 2025 60(5):461-471

Bibliography

PubMed
PMID 40342610
PubMed Central
PMC12055807
DOI
10.1177/00185787251337615
Funding
Funding disclosure was not located in the indexed record reviewed; consult the source publication for the full funding statement.
Competing interests
Competing-interest disclosure was not located in the indexed record reviewed; consult the source publication for the full declaration.

Study snapshot

DesignProspective open-label randomized controlled trial
ModelHuman
SamplePatients with hematological malignancies receiving amphotericin B deoxycholate
InterventionAmphotericin B plus oral NAC 600 mg twice daily versus amphotericin B alone
DurationDuring amphotericin B treatment
EndpointsAcute kidney injury; Renal recovery; Hypokalemia; Hypomagnesemia; Cost effectiveness

What the study showed, in plain terms

2025 randomized trial testing NAC against amphotericin B-associated nephrotoxicity.

Key findings

NAC reduced the incidence of acute kidney injury in this single-center trial and was well tolerated; renal-recovery improvement did not reach statistical significance.

What this study can and cannot tell us

Open-label, specialized oncology/hematology population and single-country study; larger replication is needed.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology